Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥：索樂匹尼布獲FDA孤兒藥資格 用於治療原發免疫性血小板減少症

Future Wealths
Future Wealths
29 10 月, 2026
One Min Read
3 Views
0 Comments
和黃醫藥(0013)宣布，索樂匹尼布（sovleplenib）獲美國食品藥品監督管理局（「FDA」）授予孤兒藥資格，用於治療原發免疫性血小板減少症。免疫性血小板減少症是一種導致出血風險增加的自身免疫疾病。索樂匹尼布是一種新型、高選擇性的口服脾酪氨酸激酶（「Syk」）抑制劑。

原文: https://finance.mingpao.com/fin/instantf/20261029/1793244895579/%E5%92%8C%E9%BB%83%E9%86%AB%E8%97%A5-%E7%B4%A2%E6%A8%82%E5%8C%B9%E5%B0%BC%E5%B8%83%E7%8D%B2fda%E5%AD%A4%E5%85%92%E8%97%A5%E8%B3%87%E6%A0%BC-%E7%94%A8%E6%96%BC%E6%B2%BB%E7%99%82%E5%8E%9F%E7%99%BC%E5%85%8D%E7%96%AB%E6%80%A7%E8%A1%80%E5%B0%8F%E6%9D%BF%E6%B8%9B%E5%B0%91%E7%97%87%22%20target=%22blank

Last Update: 29 10 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept